Jubilant Pharmova has announced robust financial results for the year ended March 31, 2026. The company reported annual revenue of ₹83,456 million, marking a significant increase from the previous year. Driven by strong operational performance, the Board has recommended a final dividend of 500%, equivalent to ₹5 per equity share, subject to shareholder approval. The company also confirmed an unmodified auditor’s report for both standalone and consolidated financial statements.
Financial Performance Highlights
Jubilant Pharmova demonstrated solid growth in FY26, reporting a consolidated annual revenue of ₹83,456 million, compared to ₹72,913 million in FY25. The profit for the period reached ₹3,975 million. These results reflect a consistent operational strategy and strong performance across key business segments, including Radiopharma and Contract Research, Development, and Manufacturing Organizations (CRDMO).
Dividend and Shareholder Value
The Board of Directors has recommended a final dividend of 500%, which translates to ₹5 per equity share with a face value of Re. 1 each for the financial year ended March 31, 2026. The record date for determining the eligibility of shareholders for this dividend has been fixed as July 24, 2026. If approved at the upcoming Annual General Meeting, the dividend will be disbursed within 30 days.
Segment and Operational Overview
The company continues to diversify its business, with segments such as Radiopharma and Allergy Immunotherapy contributing significantly to the annual revenue of ₹83,368 million (segment revenue). Despite navigating the impact of regulatory remediation and labor code adjustments, the company maintains a stable outlook. Impairment charges and restructuring expenses were accounted for as exceptional items, ensuring accurate reflection of the company’s financial health during the fiscal year.
Corporate Governance
Jubilant Pharmova confirmed that the Statutory Auditors, M/s Walker Chandiok & Co. LLP, have issued an unmodified opinion on the audited financial results for the year ended March 31, 2026. This, coupled with the review by the Audit Committee, underscores the company’s commitment to transparency and robust corporate governance practices.
Source: BSE
